ABOUT

Merlin Biotech – addressing unmet needs

MERLIN Biotech is an mRNA platform start-up innovative biotechnology spinout from the Baruch S. Blumberg Institute. MERLIN leverages proven mRNA technology to develop novel therapeutics and vaccines that address important unmet medical needs like adult and pediatric cancer, chronic hepatitis B, and Lyme disease.

OUR MANAGEMENT TEAM

MERLIN’s leadership and boards include a former Moderna Senior VP, a Nobel Laureate, and global experts in mRNA development, oncology immune-modulators, chronic hepatitis B, and preventive vaccines for Lyme disease.

VIEW THE FULL TEAM
Randall N. Hyer, MD, PhD, MPH

Randall N. Hyer, MD, PhD, MPH

Chief Executive Officer

VIEW PROFILE
Nikhil A. Heble, PharmD, JD

Nikhil A. Heble, PharmD, JD

President

VIEW PROFILE
Ju-Tao Guo, MD

Ju-Tao Guo, MD

Chief Scientific Officer

VIEW PROFILE
Louis P. Kassa, III, MPA

Louis P. Kassa, III, MPA

Chief Business Officer

VIEW PROFILE
Ian Henrich, PhD

Ian Henrich, PhD

Vice President, Research
and Development

VIEW PROFILE
Lily Paulovic

Lily Paulovic

Business Development and
Operations Manager

VIEW PROFILE